Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapyJonathan Sackner-Bernstein
Clin Cardiol 28:I19-27. 2005
....
- Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure
Jonathan D Sackner-Bernstein
Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, NY 11030, USA
Circulation 111:1487-91. 2005
..Renal function is an important prognostic factor for patients with acutely decompensated heart failure (ADHF). We investigated the renal effects of nesiritide as treatment for ADHF...
- Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure
Jonathan D Sackner-Bernstein
Clinical Scholars Program, Division of Cardiology, 1st Floor Cohen, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030, USA
Curr Cardiol Rep 7:204-10. 2005
..Patients refractory to diuretic therapy may be considered for treatment with inotropes or vasodilators, and others may be considered for venovenous ultrafiltration. The rationale for use of each therapy is reviewed...
- Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials
Jonathan D Sackner-Bernstein
Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, NY 11030, USA
JAMA 293:1900-5. 2005
..Nesiritide improves symptoms in patients with acutely decompensated heart failure compared with placebo and appears to be safer than dobutamine. Its short-term safety relative to standard diuretic and vasodilator therapies is less clear...
- Increasing organ transplantation--fairly
Jonathan D Sackner-Bernstein
Division of Cardiology, North Shore University Hospital, Manhasset, NY 11030, USA
Transplantation 77:157-9. 2004
..Such a system will encourage more donation as people on the donor list start to receive transplants themselves, especially when the transplant takes place quickly, before risk becomes excessive...
- Neurohormonal antagonism in heart failure: what is the optimal strategy?
Jonathan D Sackner-Bernstein
Division of Cardiology, St Luke s Roosevelt Hospital, New York, NY, USA
Mt Sinai J Med 71:115-26. 2004
..Overall prognosis however remains poor. We review the data from these trials to encourage clinicians to use these proven neurohormonal antagonists in optimizing therapeutic strategy...
- Practical guidelines to optimize effectiveness of beta-blockade in patients postinfarction and in those with chronic heart failure
Jonathan D Sackner-Bernstein
Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, New York 11030, USA
Am J Cardiol 93:69B-73B. 2004
..This article reviews the scientific evidence for the hierarchy of antiadrenergic agents and addresses practical issues associated with initiation of therapy and long-term management...
Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart FJames E Udelson
Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
J Card Fail 15:385-93. 2009
....
- Nesiritide for acute decompensated heart failure: does the benefit justify the risk?
Jonathan Sackner-Bernstein
Clinilabs, Inc, 423 West 55th Street, 4th Floor, New York, NY 10019, USA
Curr Cardiol Rep 9:187-93. 2007
..We conclude that with nesiritide, the risks of therapy outweigh the benefits demonstrated to date...
- Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure
Paul J Hauptman
Division of Cardiology, Saint Louis University School of Medicine, St. Louis, Missouri, USA
Am J Cardiol 98:60L-66L. 2006
..The background, methods, and statistical approaches used in this trial are reviewed in this article...
- How should diuretic-refractory, volume-overloaded heart failure patients be managed?
Jonathan D Sackner-Bernstein
Division of Cardiology, St Luke s Roosevelt Hospital Center, New York, New York, USA
J Invasive Cardiol 15:585-90. 2003
....
- New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients
Jonathan D Sackner-Bernstein
Heart Failure and Cardiomyopathy Center, Division of Cardiology, North Shore University Hospital, Manhasset, New York, USA
Rev Cardiovasc Med 4:S25-9. 2003
..The COMET (Carvedilol or Metoprolol European Trial) study reinforces this view by establishing that beta-blockers are not simply interchangeable agents...
- Robotically assisted left ventricular epicardial lead implantation for biventricular pacing
Joseph J Derose
Division of Cardiothoracic Surgery, St Luke s Roosevelt Hospital Center and Columbia University College of Physicians and Surgeons, New York, New York, USA
J Am Coll Cardiol 41:1414-9. 2003
..Ventricular resynchronization might be achieved in a minimally invasive fashion using a robotically assisted, direct left ventricular (LV) epicardial approach...
- Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction
Gregg C Fonarow
Rev Cardiovasc Med 4:S54-9. 2003
